<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Celgene Corporation

    verified_userVerify Profile
    Companies » Health Care » Pharmaceuticals & Biotechnology » Pharmaceuticals

    About Celgene Corporation

    Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through next-generation solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      Mark J. Alles
    • FOUNDED
      1986
    • EMPLOYEES
      5001-10000
    • SECTOR
      Pharmaceuticals & Biotechnology
    • SUBSECTOR
      Pharmaceuticals

    Company Tags

    No articles found.

    Organogenesis Holdings Inc.

    Organogenesis Holdings Inc.

    Organogenesis Holdings Inc. is a leading regenerative medicine company focused on ...

    Organogenesis Holdings Inc. is a leading regene...

    Filing Type:    PU
    Nymox Pharmaceutical Corporation

    Nymox Pharmaceutical Corporation

    Nymox Pharmaceutical Corporation specializes in the research and development of th...

    Nymox Pharmaceutical Corporation specializes in...

    Filing Type:    PU
    Anthera Pharmaceuticals, Inc.

    Anthera Pharmaceuticals, Inc.

    Anthera Pharmaceuticals, Inc., a development stage biopharmaceutical company, focu...

    Anthera Pharmaceuticals, Inc., a development st...

    Amount Raised:    $65,500,000
    Fundraising Status:    VT
    Filing Type:    PU
    DiaMedica Therapeutics Inc.

    DiaMedica Therapeutics Inc.

    DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company focused ...

    DiaMedica Therapeutics Inc. is a clinical stage...

    Filing Type:    PU
    Adaptimmune Therapeutics PLC

    Adaptimmune Therapeutics PLC

    Adaptimmune is a leader in TCR T-cell therapy, focused on developing novel cancer ...

    Adaptimmune is a leader in TCR T-cell therapy, ...

    Filing Type:    PU
    Axsome Therapeutics, Inc.

    Axsome Therapeutics, Inc.

    Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing...

    Axsome Therapeutics, Inc. is a clinical-stage b...

    Filing Type:    PU
    20/20 GeneSystems, Inc.

    20/20 GeneSystems, Inc.

    20/20 GeneSystems, Inc. an early stage digital diagnostics company with the core m...

    20/20 GeneSystems, Inc. an early stage digital ...

    Fundraising Status:    SASBEC
    Filing Type:    RA
    Vaccinex, Inc.

    Vaccinex, Inc.

    Vaccinex is a clinical-stage biotechnology company engaged in the discovery and de...

    Vaccinex is a clinical-stage biotechnology comp...

    Filing Type:    PU
    Check-Cap Ltd.

    Check-Cap Ltd.

    Check-Cap is a clinical-stage medical diagnostics company developing C-ScanÂŽ, the...

    Check-Cap is a clinical-stage medical diagnosti...

    Filing Type:    PU
    Dynavax Technologies Corporation

    Dynavax Technologies Corporation

    Dynavax Technologies Corporation (Nasdaq: DVAX) is a clinical-stage biopharmaceuti...

    Dynavax Technologies Corporation (Nasdaq: DVAX)...

    Filing Type:    PU
    Kiniksa Pharmaceuticals, Ltd.

    Kiniksa Pharmaceuticals, Ltd.

    We are a biopharmaceutical company focused on discovering, acquiring, developing a...

    We are a biopharmaceutical company focused on d...

    Filing Type:    PU
    Apellis Pharmaceuticals, Inc.

    Apellis Pharmaceuticals, Inc.

    We are a clinical-stage biopharmaceutical company focused on the development of no...

    We are a clinical-stage biopharmaceutical compa...

    Filing Type:    PU
    ©2026 National Investor Network. All Rights Reserved.